Sector News

Illumina Signs Agreement to Acquire GenoLogics

August 5, 2015
Life sciences
(BUSINESS WIRE) – Illumina, Inc. today announced it has signed a definitive agreement to acquire GenoLogics Life Sciences Software, a developer of industry-leading laboratory information management systems (LIMS) for life sciences organizations. The acquisition strengthens Illumina’s industry leading portfolio of genetic analysis solutions.
 
“The acquisition of GenoLogics demonstrates Illumina’s commitment to drive the adoption of sequencing in new markets and improve the genomic information workflow,” said Francis deSouza, President of Illumina. “Adding GenoLogics’ products to Illumina’s portfolio is another example of our continued commitment to bring innovative sample-to-answer solutions to research and clinical labs.”
 
Adopted by over 120 genomic labs worldwide, GenoLogics’ Clarity LIMS? software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations. GenoLogics has a number of current partnerships with Illumina, including the recently launched Clarity LIMS X, an edition of its industry-leading laboratory informatics platform that is optimized for use with Illumina SeqLab to address population-scale genomics workflows.
 
“We are excited to join Illumina and carry on the innovative spirit that GenoLogics Life Sciences Software has been known for,” said Michael Ball, CEO of GenoLogics. “Illumina and GenoLogics have had a longstanding partnership and this acquisition will enable us to widen our distribution, accelerate our product development, and provide even greater support to the Clarity LIMS community.”
 
GenoLogics will become part of the Illumina Enterprise Informatics business under the leadership of Sanjay Chikarmane, Senior Vice President and General Manager of Enterprise Informatics.
 
The impact of this transaction was contemplated in the updated 2015 financial guidance Illumina provided on July 21, 2015. The acquisition is expected to close by the end of August.
 
Source: Illumina

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.